Teladoc's operational review trims costs and narrows losses after 2023 revenue miss

Teladoc Health spent 2023 digging out of the writedown years: 2022 closed with a $13.7 billion net loss swollen by hefty non-cash goodwill impairments, and when Q3 2023 revenue missed Wall Street's forecasts the virtual care company kicked off an operational review to boost the bottom line. By the February 2024 earnings call, CEO Jason Gorevic could describe the review's shape: cost cuts through automation, internal process improvements, organizational realignments and less spending on third-party supplies, plus job cuts in engineering and data science reported by Endpoints News.

The review is expected to net about $43 million in expense savings in 2024, according to the company's earnings report. The full-year 2023 numbers behind it: revenue up 8% to $2.6 billion, a net loss of $220.4 million against the prior year's $13.7 billion, and what CFO Mala Murthy called strong free cash flow that the company expects to keep generating.

The fourth quarter told a similar story — revenue up 4% to $660.5 million with a $28.9 million net loss, beating on EPS despite missing revenue expectations — while the integrated care segment grew 8% and revenue at BetterHelp, the direct-to-consumer mental health offering, stayed flat on lower yield from social media advertising spend.

Cutting is only half of it. Gorevic said Teladoc could still make sizable investments in technology, such as machine learning and AI, to engage members on a hyper-personalized basis and stand out among competitors, and Murthy left the door open to tuck-in M&A deals, arguing free cash flow could fund debt paydown or acquisitions. Guidance for 2024 framed the ambition conservatively: revenue of $2.64 billion to $2.74 billion and a net loss per share of $0.80 to $1.10.

The review is projected to net about $43M in expense savings in 2024; 2023 revenue rose 8% to $2.6B and the net loss narrowed to $220.4M from $13.7B.

Q3 2023 revenue missed Wall Street forecasts, showing the growth story was not converting into bottom-line results.

The 2022 net loss of $13.7 billion, driven by non-cash goodwill impairments, made profitability the metric investors watched.

Cost levers — automation, process improvements, realignments, supplier spend — could be pulled without changing the strategy.

Strong free cash flow kept options open: the review funds differentiation investments and possible tuck-in M&A.

A structured operational review — automation, process fixes, org realignment — can buy room for the next bet, and free cash flow decides whether you pay down debt or buy.

The article leaves the turnaround mid-flight: the savings are projected, not banked. For 2024 Teladoc guided to $2.64–2.74 billion in revenue and a net loss per share of $0.80–$1.10, with the operational review contributing about $43 million of expense savings during the year. Management kept both levers live — sizable technology investments in machine learning and AI for hyper-personalized member engagement, and tuck-in M&A funded by free cash flow — while BetterHelp's flat revenue showed the direct-to-consumer side still needed fixing.